NEW

Stock Screener with Intrinsic Value

TRY FOR FREE

Protagonist Therapeutics, Inc. (PTGX)

Last Price$37.2(1.6%)

Market Cap$2,297.8M

LTM Net Debt

($457.8M)

YoY Growth

+43.5%

3Y CAGR

+14.4%

5Y CAGR

+28.8%

Stock quality & Intrinsic value

Start beating the S&P 500

Protagonist Therapeutics, Inc. Net Debt

Annual

Quarterly

LTM

Crunching data... Almost there!

	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23
Net Debt	($9,324.0K)	($11.9M)	($87.7M)	($155.5M)	($128.9M)	($114.8M)	($300.4M)	($318.8M)	($231.2M)	($340.5M)

PTGX

Key metrics and insights to make informed decisions.

View full analysis

Overvalued or undervalued?

Check the intrinsic value for PTGX and see if it's the right time to invest.

Dive in

Protagonist Therapeutics, Inc. (PTGX) Net Debt comparison analysis

Crunching data... Almost there!

PTGX key stats

USD

Millions

Billions

Annual

Quarterly

Trailing

Key stats

Income statement

Balance sheet

Cash Flow Statement

Valuation

Ratios

Per share

Per employee

Dividends & Yields

Crunching data... Almost there!

Discover more Stock Ideas

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%

S&P Outperformance 19.1%

Next 3M Predicted Return 20.3%

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%

S&P Outperformance 22.3%

Next 3M Predicted Return 26.8%

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.

3M Return 28.4%

S&P Outperformance 15.4%

Next 3M Predicted Return 16.9%

More ideas -->

Loved by
investors
worldwide

10K+

Investors use our platform

Top value investing hub with all necessary tools

1K+

Experienced investors in our community

4.9

Average rating across all rating platforms

Start for free ->

FAQ

1) What is Protagonist Therapeutics, Inc.'s Net Debt?

As of today, Protagonist Therapeutics, Inc.'s last 12-month Net Debt is ($457.8M), based on the financial report for Sep 30, 2024 (Q3 2024).

2) What is Protagonist Therapeutics, Inc.'s Net Debt growth rate?

Over the last year, Protagonist Therapeutics, Inc.'s Net Debt growth was 43.5%. The average annual Net Debt growth rates for Protagonist Therapeutics, Inc. have been 19.8% over the past three years, 28.8% over the past five years.

3) Is Protagonist Therapeutics, Inc.'s Net Debt growth rate Good?

Over the last year, Protagonist Therapeutics, Inc.'s Net Debt growth was 43.5%, which is higher than industry growth of (0.1%). It indicates that Protagonist Therapeutics, Inc.'s Net Debt growth is Bad.

4) How does Protagonist Therapeutics, Inc.'s Net Debt growth rate compare to its peers?

Over the last year, Protagonist Therapeutics, Inc.'s Net Debt growth was 43.5%, which is higher than peer median growth of (46.9%). The list of peers includes MRNA, SMMT, ALNY, BGNE, NVO, UTHR, VRTX, REGN, BNTX, ARGX etc.